Chemoradiation Established as New Standard in Glioma Subtypes
A study that unfolded over 17 years has established combination chemotherapy after radiotherapy as a new standard of care for patients with anaplastic oligodendroglial tumors that contain 1p/19q chromosomal co-deletions.
Combination of Aflibercept and Topotecan Shows Activity in Patients With Small Cell Lung Cancer
Aflibercept combined with topotecan achieved slightly higher rates of PFS and disease control in patients with platinum-refractory, extensive-stage small cell lung cancer, compared with topotecan alone.
Cabozantinib Submitted for FDA Approval After Positive Phase III Thyroid Cancer Trial
The tyrosine kinase inhibitor cabozantinib met its primary endpoint of progression-free survival in patients with advanced medullary thyroid cancer.
Tivantinib Achieves Advantage for Patients With HCC
Tivantinib has demonstrated statistically significant improvements in time to progression and overall survival versus placebo among patients with unresectable hepatocellular carcinoma.
Ponatinib Achieves Primary Endpoints in CML Subtypes
Ponatinib, an oral multikinase inhibitor, generated significant responses in more than 50% of patients with certain chronic myeloid leukemia subtypes.
Regorafenib Extends Survival in Colorectal Cancer, Delays Disease Progression in GIST
The oral multikinase inhibitor regorafenib extended OS in patients with metastatic colorectal cancer and improved PFS in patients with gastrointestinal stromal tumors.
Older Women With Early Cervical Cancer Are Less Likely to Have Surgery
Among patients with early-stage cervical cancer, women aged greater than 65 years are less likely than younger women to be treated with surgery as compared with chemoradiation.
Abiraterone Acetate Significantly Improves PFS in Metastatic Prostate Cancer
An interim analysis of the COU-AA-302 trial investigating the use of abiraterone acetate (Zytiga) in chemotherapy-naÃ¯ve patients with mCRPC showed a trend toward improvement in PFS and OS.
Carfilzomib Shows Promise as Alternative to Bortezomib in Multiple Myeloma
Two separate clinical trials presented at ASCO 2012 suggest that carfilzomib would be a safe and effective alternative to bortezomib for the treatment of multiple myeloma, following progression.
Maintenance Erlotinib Fails to Improve Survival in Ovarian Cancer
Erlotinib given as a maintenance therapy did not improve PFS or OS in patients with epithelial ovarian cancer who had received first-line platinum-based chemotherapy.
Research Further Supports Aflibercept Benefit in Metastatic Colorectal Cancer
The phase III VELOUR trial demonstrated that the addition of aflibercept to FOLFIRI improved overall survival compared with placebo plus FOLFIRI in patients with metastatic colorectal cancer.
Studies Support Efficacy of Axitinib as First- and Second-Line Kidney Cancer Treatment
Research presented at ASCO 2012 demonstrated the efficacy of axitinib (Inlyta) as both a first- and second-line treatment in patients with metastatic renal cell carcinoma.
Heat-Shock Protein Inhibitor Delays Disease Progression in Phase II Trial
The novel agent OGX-427 delayed disease progression in chemotherapy-naÃ¯ve patients with metastatic castration-resistant prostate cancer, according to the preliminary results.
Plenary Sunday at ASCO
A well-designed study involving hundreds of patients for many years can lead to one- to two-sentence conclusions that create the new standard of care; this year's Plenary Session on Sunday at ASCO was no exception.
Study Supports Feasibility of Routine Molecular Screening of NSCLC in Community Setting
New study reveals that widespread molecular screening of nonâ€“small cell lung cancer is feasible and can be performed outside of large academic medical centers.
Sipuleucel-T Studies Support Earlier Use, Reveal Potential Biomarker
Research presented at ASCO 2012 examined the expanded use of sipuleucel-T, as well as methods to determine which patients might benefit the most from the therapy.
Lapatinib Equivalent to Trastuzumab as Neoadjuvant Therapy, but Less Effective in Metastatic Setting
Two phase III studies presented at ASCO 2012 explored the role of lapatinib in the treatment of HER2-positive breast cancer.
Tivozanib Improves PFS Versus Sorafenib in Patients With Renal Cell Carcinoma
Tivozanib increased progression-free survival and objective responseÂ rate in patients with renal cell carcinoma compared with sorafenib.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512